Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SYN-2510
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : ImmuneOnco
Deal Size : $2,050.0 million
Deal Type : Licensing Agreement
Instil Bio and ImmuneOnco Announce License Agreement for IMM2510 and IMM27M Antibodies
Details : Instil is the in-licensing agreement with ImmuneOnc for ex-China development and commercial rights of ImmueOnco’s PD-L1xVEGF bispecific antibody, IMM2510 for the treating advanced solid tumors.
Product Name : IMM2510
Product Type : Large molecule
Upfront Cash : $50.0 million
August 01, 2024
Lead Product(s) : SYN-2510
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : ImmuneOnco
Deal Size : $2,050.0 million
Deal Type : Licensing Agreement
Lead Product(s) : ITIL-306,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ITIL-306 is an autologous TIL cell therapy engineered with CoStAR molecule (activated by folate receptor alpha), which enhances the cytokine release, cytolytic activity, and proliferation of TILs in the t...
Product Name : ITIL-306
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
January 09, 2023
Lead Product(s) : ITIL-306,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ITIL-168 is an investigational, autologous cell therapy made from tumor infiltrating lymphocytes, or TILs. ITIL-168 is manufactured with Instil’s proprietary, which has been designed to capture and pres...
Product Name : ITIL-168
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 31, 2022
Details : ITIL-306 is an autologous TIL cell therapy engineered with a novel and proprietary CoStAR molecule that is activated by folate receptor alpha (FRα) to provide robust costimulatory signals within the tumo...
Product Name : ITIL-306
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 18, 2022
Lead Product(s) : ITIL-306,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ITIL-306 is an autologous TIL cell therapy engineered with a novel and proprietary Costimulatory Antigen Receptor (CoStAR) that is activated by folate receptor alpha (FRα) to provide robust costimulatory...
Product Name : ITIL-306
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 27, 2022
Lead Product(s) : ITIL-306,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ITIL-168 is an investigational, autologous cell therapy made from tumor infiltrating lymphocytes, or TILs used in patients with checkpoint inhibitor-refractory advanced cutaneous melanoma.
Product Name : ITIL-168
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 16, 2021
Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma
Details : ITIL-168 is an investigational, autologous cell therapy made from tumor infiltrating lymphocytes, or TILs. ITIL-168 is manufactured with Instil’s proprietary which has been designed to capture and prese...
Product Name : ITIL-168
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 27, 2021
Cancer Biotech Instil Bio Raises Deal Size by 25% Ahead of $312 Million IPO
Details : Instil Bio is developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL) therapies for the treatment of cancer. Its lead TIL candidate, ITIL-168, is being developed for the treat...
Product Name : ITIL-168
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 18, 2021
LOOKING FOR A SUPPLIER?